BioLife Solutions (BLFS) Financials

$21.83 -0.49 (-2.20%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$21.88 +0.05 (+0.21%)

As of 05/30/2025 06:42 PM Eastern

Annual Income Statements for BioLife Solutions

This table shows BioLife Solutions' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-20	-68	-140	-8.91	1.98	-1.66	-25	-2.73	-6.88	-4.21	-3.22
Consolidated Net Income / (Loss)	-20	-68	-140	-8.91	1.98	-1.66	-25	-2.52	-8.04	-5.00	-3.30
Net Income / (Loss) Continuing Operations	-11	-18	0.39	-8.91	1.98	-1.66	-25	-2.52	-8.04	-5.00	-3.30
Total Pre-Tax Income	-11	-18	-4.85	-29	-1.28	-3.20	-25	-2.52	-8.04	-5.00	-3.30
Total Operating Income	-7.13	-23	-5.92	-35	-6.24	-0.22	3.66	-1.06	-4.85	-5.02	-3.14
Total Gross Profit	54	46	47	37	27	19	14	6.75	4.78	3.81	3.04
Total Revenue	82	76	76	119	48	27	20	11	8.23	6.45	6.19
Operating Revenue	82	76	76	119	48	27	20	11	8.23	6.45	6.19
Total Cost of Revenue	29	30	29	82	21	8.76	6.22	4.28	3.45	2.63	3.16
Operating Cost of Revenue	29	30	29	82	21	8.76	6.22	4.28	3.45	2.63	3.16
Total Operating Expenses	61	69	53	72	34	19	9.86	7.80	9.63	8.83	6.17
Selling, General & Admin Expense	41	43	33	34	15	8.89	5.95	4.52	4.59	4.87	3.97
Marketing Expense	9.61	13	12	14	6.41	4.70	2.62	2.09	3.01	2.58	1.33
Research & Development Expense	7.91	12	8.67	12	6.72	3.17	1.30	1.19	2.03	1.38	0.87
Amortization Expense	2.74	3.52	3.99	8.20	3.03	1.08	0.00	-	-	-	-
Other Special Charges / (Income)	0.00	-2.19	-4.75	2.88	1.58	0.05	0.00	-	-	-	-
Total Other Income / (Expense), net	-4.30	4.97	1.08	6.13	4.96	-2.98	-29	-1.46	-3.19	0.02	-0.17
Interest & Investment Income	-4.79	-1.45	0.41	5.97	1.36	9.87	-0.39	-1.01	-2.79	0.00	-
Other Income / (Expense), net	0.50	6.42	0.66	0.17	3.60	13	-28	-0.11	0.00	0.02	0.01
Income Tax Expense	-0.04	-0.02	-5.24	-20	-3.26	-1.54	0.00	0.00	-	-	-
Net Income / (Loss) Discontinued Operations	-8.80	-50	-140	-	-	-	-	-	-	-	-
Basic Earnings per Share	($0.44)	($1.55)	($3.29)	($0.23)	$0.07	($0.09)	($1.56)	($0.21)	($0.54)	($0.35)	($0.31)
Weighted Average Basic Shares Outstanding	46.07M	43.72M	42.48M	38.50M	27.31M	19.46M	16.26M	13.26M	12.64M	12.18M	10.45M
Diluted Earnings per Share	($0.44)	($1.55)	($3.25)	($0.23)	($0.06)	($0.09)	($1.56)	($0.21)	($0.54)	($0.35)	($0.31)
Weighted Average Diluted Shares Outstanding	46.07M	43.72M	43.07M	38.50M	27.31M	19.46M	16.26M	13.26M	12.64M	12.18M	10.45M
Weighted Average Basic & Diluted Shares Outstanding	47M	45.30M	43.21M	38.50M	27.31M	19.46M	16.26M	13.26M	12.64M	12.18M	10.45M

This table shows BioLife Solutions' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-0.45	12	-1.70	-21	-10	-15	-29	-10	-14	-49	-10
Consolidated Net Income / (Loss)	-0.45	12	-1.70	-21	-10	-15	-29	-10	-14	-49	-10
Net Income / (Loss) Continuing Operations	-0.45	7.68	-1.70	-7.15	-10	17	-16	-5.52	-14	91	-10
Total Pre-Tax Income	-0.43	7.54	-1.73	-7.15	-10	16	-16	-5.52	-14	91	-11
Total Operating Income	-1.22	7.35	-1.56	-2.80	-10	16	-15	-11	-14	90	-12
Total Gross Profit	16	9.92	16	15	13	8.88	12	11	14	7.06	14
Total Revenue	24	-8.37	31	28	32	-15	24	29	38	-41	41
Operating Revenue	24	-8.37	31	28	32	-15	24	29	38	-41	41
Total Cost of Revenue	8.16	-18	14	13	19	-24	12	18	24	-48	27
Operating Cost of Revenue	8.16	-18	14	13	19	-24	12	18	24	-48	27
Total Operating Expenses	17	2.57	18	18	23	-7.39	27	22	28	-83	25
Selling, General & Admin Expense	12	5.36	11	11	13	4.07	11	14	15	-1.84	12
Marketing Expense	2.60	-2.51	3.54	3.50	5.07	-2.47	4.88	3.83	6.47	-3.91	5.28
Research & Development Expense	2.20	-0.05	2.05	2.38	3.53	0.39	3.74	3.79	4.15	-1.96	3.43
Amortization Expense	0.70	0.00	0.91	0.91	0.91	-0.66	1.31	1.41	1.46	-4.25	2.51
Total Other Income / (Expense), net	0.78	0.19	-0.17	-4.35	0.04	0.09	-0.21	5.11	-0.02	0.36	0.82
Interest & Investment Income	0.68	0.12	-0.27	-4.44	-0.21	-0.20	-0.45	-0.39	-0.41	-	0.68
Other Income / (Expense), net	0.10	0.07	0.10	0.08	0.25	0.29	0.24	5.50	0.39	0.41	0.14
Income Tax Expense	0.01	-0.14	-0.03	0.00	0.13	-0.23	0.12	0.00	0.09	-0.30	-0.60
Net Income / (Loss) Discontinued Operations	0.00	-	0.00	-14	-	-	-13	-4.68	-	-	-
Basic Earnings per Share	($0.01)	$0.27	($0.04)	($0.45)	($0.22)	($0.33)	($0.67)	($0.23)	($0.32)	($1.15)	($0.24)
Weighted Average Basic Shares Outstanding	46.69M	46.07M	46.18M	25.29M	45.43M	43.72M	14.44M	43.44M	43.03M	42.48M	42.65M
Diluted Earnings per Share	($0.01)	$0.27	($0.04)	($0.45)	($0.22)	($0.33)	($0.67)	($0.23)	($0.32)	-	($0.24)
Weighted Average Diluted Shares Outstanding	47.13M	46.07M	46.18M	46.00M	45.43M	43.72M	43.57M	43.44M	43.03M	43.07M	42.65M
Weighted Average Basic & Diluted Shares Outstanding	47.56M	47M	46.39M	46.14M	46.03M	45.30M	44.03M	43.49M	43.46M	43.21M	42.77M

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	60	16	-50	-21	84	-15	24	5.26	-0.77	-0.37	2.38
Net Cash From Operating Activities	8.43	-12	-8.49	-4.59	6.65	1.21	2.35	0.61	-4.33	-4.97	-3.16
Net Cash From Continuing Operating Activities	8.43	-12	-8.49	-4.59	6.65	11	2.35	0.61	-4.33	-4.97	-3.16
Net Income / (Loss) Continuing Operations	-20	-68	-140	-8.91	1.98	-1.66	-25	-2.52	-8.04	-5.00	-3.30
Consolidated Net Income / (Loss)	-20	-68	-140	-8.91	1.98	-1.66	-25	-2.52	-8.04	-5.00	-3.30
Depreciation Expense	5.16	7.11	6.78	4.66	2.04	0.72	0.34	0.34	0.37	0.34	0.26
Amortization Expense	3.03	3.93	9.27	8.32	3.03	1.08	0.00	0.03	0.09	-0.04	0.07
Non-Cash Adjustments To Reconcile Net Income	20	45	140	19	2.17	16	30	2.45	3.81	0.55	0.65
Changes in Operating Assets and Liabilities, net	0.16	-0.79	-25	-28	-2.58	-5.24	-3.22	0.30	-0.56	-0.83	-0.85
Net Cash From Investing Activities	58	18	-58	-13	-25	-27	-6.50	-0.14	0.39	4.24	-8.14
Net Cash From Continuing Investing Activities	58	18	-58	-13	-25	-27	-6.50	-0.14	0.39	4.24	-8.14
Purchase of Property, Plant & Equipment	-3.23	-6.38	-10	-8.39	-1.96	-0.68	-0.50	-0.14	-1.26	-1.42	-0.59
Acquisitions	-0.30	0.00	0.00	-	-15	-23	-6.00	-	-	-	-
Purchase of Investments	-18	-27	-53	0.00	0.00	-1.00	0.00	0.00	-	-1.41	-7.95
Divestitures	73	0.00	0.00	1.56	0.00	1.25	-	-	-	-	-
Sale and/or Maturity of Investments	22	56	8.92	0.00	0.00	-	-	-	1.65	7.07	0.40
Other Investing Activities, net	-15	-4.86	-3.54	-6.37	-7.84	-3.16	0.00	-	-	-	-
Net Cash From Financing Activities	-6.78	11	16	-2.78	102	1.60	28	4.80	3.17	0.37	14
Net Cash From Continuing Financing Activities	-6.78	11	16	-2.78	96	1.60	28	4.80	3.17	0.37	14
Repayment of Debt	-6.68	-0.43	-2.50	-32	-2.23	-0.16	-0.07	-0.01	0.00	0.00	-
Repurchase of Common Equity	0.00	0.00	-0.13	-0.15	-6.20	0.00	-	-0.05	-0.11	0.00	-
Issuance of Debt	0.00	0.00	20	29	3.16	0.00	-	1.00	3.00	-	-
Issuance of Common Equity	0.00	10	0.00	0.00	100	0.00	20	0.00	-	-	14
Other Financing Activities, net	-0.10	0.78	-1.05	0.39	1.03	1.76	13	3.97	0.28	0.37	0.08
Other Net Changes in Cash	0.00	0.04	-0.11	-	-	-	-	-	-	-	-
Cash Interest Paid	1.61	1.93	0.59	0.45	0.00	0.00	-	-	-	-	-

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-28	71	2.08	-7.68	-5.65	16	-2.11	2.28	-0.35	-7.66	3.02
Net Cash From Operating Activities	1.73	1.65	4.80	6.46	-4.48	2.31	-4.38	-7.72	-2.71	7.86	1.50
Net Cash From Continuing Operating Activities	1.73	1.65	4.80	6.46	-4.48	2.31	-4.38	-7.72	-2.71	7.86	1.50
Net Income / (Loss) Continuing Operations	-0.45	12	-1.70	-21	-10	-15	-29	-10	-14	-49	-10
Consolidated Net Income / (Loss)	-0.45	12	-1.70	-21	-10	-15	-29	-10	-14	-49	-10
Depreciation Expense	0.68	0.94	1.41	1.45	1.36	1.47	1.92	2.00	1.72	1.72	1.80
Amortization Expense	0.60	0.70	0.82	0.77	0.73	0.70	1.05	1.10	1.08	1.03	2.51
Non-Cash Adjustments To Reconcile Net Income	4.83	-15	4.46	22	8.62	11	25	-0.10	8.73	54	7.22
Changes in Operating Assets and Liabilities, net	-3.94	2.18	-0.18	3.13	-4.97	3.68	-3.42	-0.52	-0.53	0.77	0.29
Net Cash From Investing Activities	-27	74	-1.68	-13	-0.22	3.96	1.66	9.29	2.93	-15	-16
Net Cash From Continuing Investing Activities	-27	74	-1.68	-13	-0.22	3.96	1.66	9.29	2.93	-15	-16
Purchase of Property, Plant & Equipment	-0.18	-0.76	-1.11	-1.00	-0.36	-0.98	-1.50	-0.61	-3.30	-4.45	-2.45
Purchase of Investments	-30	-2.40	-5.30	-4.34	-6.37	-4.41	-6.96	-7.53	-8.20	-17	-13
Sale and/or Maturity of Investments	3.57	3.71	5.17	6.07	6.97	11	11	19	15	8.17	0.75
Other Investing Activities, net	-0.25	-0.04	-0.43	-14	-0.46	-1.40	-0.90	-1.55	-1.00	-1.27	-1.50
Net Cash From Financing Activities	-2.99	-4.09	-1.04	-0.70	-0.95	9.84	0.61	0.70	-0.56	-0.63	17
Net Cash From Continuing Financing Activities	-2.99	-4.09	-1.04	-0.70	-0.95	9.84	0.61	0.70	-0.56	-0.63	17
Repayment of Debt	-2.49	-3.48	-2.70	-0.28	-0.23	0.17	-0.33	-0.15	-0.12	-0.08	-2.19
Other Financing Activities, net	-0.50	-0.60	1.66	-0.43	-0.73	-0.58	0.94	0.86	-0.44	-0.55	-0.27
Cash Interest Paid	0.27	0.37	0.41	0.38	0.45	0.53	0.46	0.44	0.50	0.36	0.11

This table presents BioLife Solutions' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	399	413	450	554	235	93	45	12	7.93	12	16
Total Current Assets	149	121	138	126	115	24	38	9.93	4.63	6.97	12
Cash & Equivalents	95	28	19	70	90	6.45	31	6.66	1.41	2.17	2.54
Short-Term Investments	9.20	16	43	0.00	-	-	-	-	-	1.65	7.40
Accounts Receivable	9.17	7.90	34	23	8.01	5.35	3.05	1.02	1.19	0.93	0.90
Inventories, net	29	27	35	28	12	11	3.51	1.85	1.76	1.83	0.97
Prepaid Expenses	6.00	4.67	6.88	4.66	4.65	1.35	0.35	0.40	0.27	0.38	0.36
Other Current Nonoperating Assets	0.00	37	-	-	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	6.08	5.69	24	18	10	5.57	1.32	1.11	1.19	1.45	1.66
Total Noncurrent Assets	245	286	288	411	110	63	6.58	1.11	2.11	3.95	2.25
Long-Term Investments	5.62	5.62	6.40	4.37	5.87	2.50	6.55	1.07	-	-	-
Goodwill	212	212	225	225	58	34	0.00	-	-	-	-
Intangible Assets	9.56	12	32	152	31	22	0.00	-	-	2.22	2.22
Other Noncurrent Operating Assets	17	14	25	29	15	5.01	0.04	0.04	2.11	1.73	0.04
Other Noncurrent Nonoperating Assets	0.00	43	-	-	-	-	-	-	-	-	-
Total Liabilities & Shareholders' Equity	399	413	450	554	235	93	45	12	7.93	12	16
Total Liabilities	51	75	86	76	30	49	31	2.05	4.76	2.51	2.14
Total Current Liabilities	33	42	45	43	16	7.67	1.94	1.51	1.13	1.73	1.26
Short-Term Debt	11	6.29	3.95	5.99	3.25	0.38	0.00	-	-	-	-
Accounts Payable	3.57	2.27	15	15	3.67	3.12	0.72	0.69	0.71	1.03	0.47
Accrued Expenses	12	9.12	18	16	4.76	3.37	1.22	0.20	0.12	0.15	0.12
Current Deferred & Payable Income Tax Liabilities	4.26	4.40	4.15	2.59	-	-	-	-	-	-	-
Other Current Liabilities	1.51	1.29	3.02	2.91	3.90	0.80	0.00	-	-	-	0.13
Other Current Nonoperating Liabilities	0.00	19	-	-	-	-	-	-	-	-	-
Total Noncurrent Liabilities	18	33	41	34	14	42	29	0.54	3.63	0.78	0.87
Long-Term Debt	5.00	18	24	6.35	0.66	-	-	-	2.84	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	0.12	0.11	0.25	5.49	0.00	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	13	8.70	17	21	13	42	29	0.05	0.10	0.00	-
Other Noncurrent Nonoperating Liabilities	0.00	6.50	-	-	-	-	-	-	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	349	338	364	478	205	43	15	10	3.17	9.86	14
Total Preferred & Common Equity	349	338	364	478	205	43	15	10	3.17	8.51	12
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Total Common Equity	349	338	364	478	205	43	15	10	3.17	8.51	12
Common Stock	684	653	612	585	303	144	113	84	74	73	72
Retained Earnings	-335	-315	-247	-107	-97	-100	-98	-74	-71	-64	-60
Accumulated Other Comprehensive Income / (Loss)	0.02	-0.35	-0.68	-0.28	0.00	-	-	-	-	-	-

This table presents BioLife Solutions' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	395	382	375	402	411	433	446	488
Total Current Assets	131	89	88	112	117	120	133	136
Cash & Equivalents	67	24	22	30	19	21	19	27
Short-Term Investments	22	10	12	16	22	25	36	35
Accounts Receivable	9.17	18	18	19	25	27	30	32
Inventories, net	28	32	32	43	43	39	41	34
Prepaid Expenses	5.82	4.91	3.48	4.41	7.85	7.99	6.20	8.04
Plant, Property, & Equipment, net	6.61	18	17	21	21	26	26	22
Total Noncurrent Assets	257	275	270	269	273	287	288	330
Long-Term Investments	20	5.88	3.68	5.07	6.23	6.91	7.09	5.07
Goodwill	212	225	225	225	225	225	225	225
Intangible Assets	8.86	18	19	20	22	29	31	74
Other Noncurrent Operating Assets	16	25	22	19	20	25	25	25
Total Liabilities & Shareholders' Equity	395	382	375	402	411	433	446	488
Total Liabilities	43	56	54	68	79	81	88	79
Total Current Liabilities	28	32	31	39	43	40	47	37
Short-Term Debt	10	12	11	8.62	5.09	2.02	4.55	4.74
Accounts Payable	3.30	3.84	4.21	4.98	12	11	16	13
Accrued Expenses	8.21	8.64	8.31	17	17	19	20	16
Current Deferred & Payable Income Tax Liabilities	3.93	4.35	4.86	5.40	5.47	4.99	4.59	-
Other Current Liabilities	1.84	3.11	2.82	3.00	3.30	3.34	3.07	2.93
Total Noncurrent Liabilities	15	24	23	30	37	41	41	42
Long-Term Debt	2.50	7.82	10	16	21	24	24	24
Noncurrent Deferred & Payable Income Tax Liabilities	0.13	0.10	0.19	0.19	0.29	0.26	0.26	0.39
Other Noncurrent Operating Liabilities	12	15	11	13	14	16	17	18
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	353	325	321	333	332	352	358	408
Total Preferred & Common Equity	353	325	321	333	332	352	358	408
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	353	325	321	333	332	352	358	408
Common Stock	688	673	668	659	633	623	619	604
Retained Earnings	-336	-348	-346	-325	-300	-271	-261	-195
Accumulated Other Comprehensive Income / (Loss)	0.03	-0.21	-0.56	-0.57	-0.66	-0.50	-0.53	-1.26

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.44%	-0.50%	-36.02%	147.79%	75.69%	38.64%	79.11%	33.97%	27.57%	4.17%	-30.83%
EBITDA Growth	126.02%	-155.43%	149.00%	-1,006.34%	-83.14%	159.33%	-2,949.12%	81.86%	6.40%	-67.94%	-20,219.94%
EBIT Growth	61.04%	-223.55%	84.97%	-1,225.45%	-120.95%	151.21%	-2,014.18%	76.00%	2.90%	-59.93%	-813.46%
NOPAT Growth	69.59%	-295.75%	83.15%	-463.37%	-2,736.82%	-106.01%	446.78%	78.23%	3.30%	-60.00%	-998.87%
Net Income Growth	70.32%	51.36%	-1,469.43%	-549.22%	219.67%	93.37%	-894.23%	68.72%	-60.98%	-51.34%	-204.46%
EPS Growth	71.61%	52.31%	-1,313.04%	-283.33%	33.33%	94.23%	-642.86%	61.11%	-54.29%	-12.90%	-40.91%
Operating Cash Flow Growth	167.46%	-47.24%	-84.80%	-169.12%	447.82%	-48.34%	288.10%	113.98%	13.01%	-57.29%	-2,265.87%
Free Cash Flow Firm Growth	-103.96%	-45.37%	127.23%	-298.70%	-42.89%	-309.53%	1,725.58%	176.62%	64.58%	38.47%	-1,752.95%
Invested Capital Growth	-1.19%	-20.20%	-22.46%	269.06%	223.47%	254.53%	-1,056.89%	-48.77%	-23.70%	50.95%	241.54%
Revenue Q/Q Growth	-42.63%	-43.72%	-50.75%	23.38%	15.44%	11.58%	13.33%	8.73%	5.52%	2.37%	-9.08%
EBITDA Q/Q Growth	104.30%	91.56%	111.20%	-66.71%	-93.09%	135.34%	-1,029.67%	19.63%	16.42%	-16.36%	-17.70%
EBIT Q/Q Growth	85.24%	79.34%	95.39%	-51.55%	-108.61%	130.17%	-1,119.70%	20.53%	13.76%	-9.12%	-28.06%
NOPAT Q/Q Growth	84.37%	73.66%	94.84%	-59.07%	-119.91%	-113.90%	6.74%	27.92%	13.80%	-8.66%	-29.78%
Net Income Q/Q Growth	56.15%	33.48%	-31.44%	-321.32%	-74.51%	94.82%	-1,477.52%	54.46%	-36.82%	-8.83%	-18.32%
EPS Q/Q Growth	56.44%	0.00%	0.00%	0.00%	66.67%	96.10%	-4,000.00%	48.78%	-45.95%	-6.06%	-34.78%
Operating Cash Flow Q/Q Growth	-7.32%	-79.78%	50.42%	-194.05%	96.31%	-56.69%	-8.49%	169.86%	12.22%	-13.03%	-32.48%
Free Cash Flow Firm Q/Q Growth	92.59%	1,279.40%	419.61%	9.78%	-34.59%	1.38%	-46.39%	-5.87%	63.73%	22.01%	-58.91%
Invested Capital Q/Q Growth	-16.83%	-17.41%	-12.76%	-1.44%	52.06%	132.20%	49.28%	-46.19%	-34.31%	9.11%	142.61%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	65.25%	60.55%	61.53%	31.09%	57.07%	68.00%	68.51%	61.20%	58.09%	59.15%	49.03%
EBITDA Margin	1.89%	-7.88%	14.14%	-18.47%	5.05%	52.61%	-122.94%	-7.22%	-53.35%	-72.71%	-45.10%
Operating Margin	-8.67%	-30.90%	-7.77%	-29.51%	-12.98%	-0.80%	18.55%	-9.58%	-58.97%	-77.80%	-50.65%
EBIT Margin	-8.06%	-22.44%	-6.90%	-29.37%	-5.49%	46.04%	-124.65%	-10.56%	-58.96%	-77.46%	-50.45%
Profit (Net Income) Margin	-24.54%	-89.65%	-183.38%	-7.48%	4.12%	-6.05%	-126.66%	-22.82%	-97.74%	-77.46%	-53.32%
Tax Burden Percent	176.67%	368.16%	2,883.77%	30.69%	-154.80%	51.81%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	172.27%	108.51%	92.15%	82.95%	48.52%	-25.38%	101.61%	216.07%	165.79%	100.00%	105.68%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-1.95%	-5.65%	-1.12%	-9.30%	-5.91%	-2.50%	0.00%	-21.23%	-63.84%	-70.01%	-374.17%
ROIC Less NNEP Spread (ROIC-NNEP)	15.49%	79.47%	262.62%	-29.69%	-18.49%	4.06%	0.00%	35.19%	325.47%	-48.45%	-809.13%
Return on Net Nonoperating Assets (RNNOA)	-3.93%	-13.73%	-32.08%	6.69%	7.51%	-3.20%	0.00%	-16.71%	-59.63%	28.03%	-618.86%
Return on Equity (ROE)	-5.88%	-19.38%	-33.20%	-2.61%	1.59%	-5.71%	-202.27%	-37.94%	-123.47%	-41.99%	-993.02%
Cash Return on Invested Capital (CROIC)	-0.76%	16.82%	24.17%	-124.02%	-111.46%	-165.15%	0.00%	43.26%	-36.95%	-110.62%	-225.56%
Operating Return on Assets (OROA)	-1.63%	-3.95%	-1.05%	-8.87%	-1.61%	18.23%	-85.43%	-11.60%	-47.80%	-35.13%	-32.16%
Return on Assets (ROA)	-4.97%	-15.76%	-27.84%	-2.26%	1.21%	-2.40%	-86.81%	-25.06%	-79.24%	-35.13%	-33.98%
Return on Common Equity (ROCE)	-5.88%	-19.38%	-33.20%	-2.61%	1.59%	-5.71%	-202.27%	-37.94%	-110.67%	-35.84%	2,192.11%
Return on Equity Simple (ROE_SIMPLE)	-5.78%	-20.14%	-38.39%	-1.86%	0.97%	-3.81%	-170.89%	-24.92%	-253.98%	-58.71%	-27.96%
Net Operating Profit after Tax (NOPAT)	-4.99	-16	-4.15	-25	-4.37	-0.15	2.56	-0.74	-3.40	-3.51	-2.19
NOPAT Margin	-6.07%	-21.63%	-5.44%	-20.66%	-9.09%	-0.56%	12.98%	-6.71%	-41.28%	-54.46%	-35.46%
Net Nonoperating Expense Percent (NNEP)	-17.44%	-85.12%	-263.74%	20.39%	12.58%	-6.57%	-122.70%	-56.42%	-389.31%	-21.56%	434.97%
Return On Investment Capital (ROIC_SIMPLE)	-1.37%	-4.54%	-1.06%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	34.75%	39.45%	38.47%	68.91%	42.93%	32.00%	31.49%	38.80%	41.91%	40.86%	50.97%
SG&A Expenses to Revenue	49.29%	57.04%	43.62%	28.26%	31.76%	32.49%	30.14%	41.04%	55.82%	75.50%	64.13%
R&D to Revenue	9.62%	15.92%	11.37%	9.92%	13.97%	11.57%	6.57%	10.82%	24.66%	21.38%	14.07%
Operating Expenses to Revenue	73.92%	91.45%	69.30%	60.60%	70.04%	68.80%	49.96%	70.79%	117.06%	136.94%	99.68%
Earnings before Interest and Taxes (EBIT)	-6.63	-17	-5.26	-35	-2.64	13	-25	-1.16	-4.85	-5.00	-3.12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1.56	-5.98	11	-22	2.43	14	-24	-0.80	-4.39	-4.69	-2.79
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.45	2.12	2.14	3.25	6.36	7.62	15.21	8.10	6.55	3.12	1.68
Price to Tangible Book Value (P/TBV)	9.48	6.31	7.25	15.34	11.28	0.00	15.21	8.10	6.55	4.22	2.07
Price to Revenue (P/Rev)	14.64	9.43	10.21	13.03	27.16	12.09	11.27	7.42	2.52	4.12	3.20
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	658.52	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.36	2.68	2.28	3.58	10.75	9.24	0.00	31.39	4.82	3.99	3.00
Enterprise Value to Revenue (EV/Rev)	13.49	9.09	9.67	12.51	25.23	11.78	9.39	6.72	2.70	3.74	1.94
Enterprise Value to EBITDA (EV/EBITDA)	713.79	0.00	68.36	0.00	499.76	22.39	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	25.58	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	72.31	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	131.65	0.00	0.00	0.00	182.61	265.74	78.94	122.40	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	14.12	8.25	0.00	0.00	0.00	6.74	49.17	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.05	0.07	0.08	0.03	0.02	0.01	0.00	0.00	0.90	0.00	0.00
Long-Term Debt to Equity	0.01	0.05	0.07	0.01	0.00	0.00	0.00	0.00	0.90	0.00	0.00
Financial Leverage	-0.25	-0.17	-0.12	-0.23	-0.41	-0.79	-1.82	-0.47	-0.18	-0.58	0.76
Leverage Ratio	1.18	1.23	1.19	1.15	1.32	2.38	2.33	1.51	1.56	1.20	29.22
Compound Leverage Factor	2.04	1.33	1.10	0.96	0.64	-0.60	2.37	3.27	2.58	1.20	30.88
Debt to Total Capital	4.37%	6.60%	7.11%	2.57%	1.87%	0.86%	0.00%	0.00%	47.32%	0.00%	0.00%
Short-Term Debt to Total Capital	3.00%	1.74%	1.01%	1.22%	1.55%	0.86%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	1.37%	4.86%	6.10%	1.35%	0.32%	0.00%	0.00%	0.00%	47.32%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	13.70%	15.30%
Common Equity to Total Capital	95.63%	93.40%	92.89%	97.43%	98.13%	99.14%	100.00%	100.00%	52.68%	86.30%	84.70%
Debt to EBITDA	10.25	-3.99	2.59	-0.57	1.61	0.03	0.00	0.00	-0.65	0.00	0.00
Net Debt to EBITDA	-60.62	4.34	-3.83	2.80	-38.06	-0.60	0.00	0.00	-0.33	0.00	0.00
Long-Term Debt to EBITDA	3.21	-2.94	2.22	-0.30	0.27	0.00	0.00	0.00	-0.65	0.00	0.00
Debt to NOPAT	-3.19	-1.45	-6.72	-0.51	-0.90	-2.45	0.00	0.00	-0.84	0.00	0.00
Net Debt to NOPAT	18.89	1.58	9.95	2.50	21.15	55.66	0.00	0.00	-0.42	0.00	0.00
Long-Term Debt to NOPAT	-1.00	-1.07	-5.77	-0.27	-0.15	0.00	0.00	0.00	-0.84	0.00	0.00
Altman Z-Score	13.61	4.93	5.04	12.13	26.58	3.47	0.89	16.82	-10.41	-1.23	0.89
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.37%	14.64%	320.75%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.54	2.86	3.11	2.95	7.37	3.14	19.37	6.56	4.08	4.04	9.64
Quick Ratio	3.48	1.23	2.17	2.18	6.32	1.54	17.38	5.08	2.29	2.75	8.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.93	49	89	-328	-82	-58	27	1.51	-1.97	-5.55	-9.02
Operating Cash Flow to CapEx	261.26%	-195.86%	-81.73%	-54.81%	345.02%	179.70%	469.60%	420.14%	-344.17%	-350.84%	-540.31%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	5,499.08	4.35	-4.85	0.00	-50.86
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	469.60	1.75	-10.68	0.00	-17.84
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	369.60	1.33	-13.78	0.00	-21.14
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.20	0.18	0.15	0.30	0.29	0.40	0.69	1.10	0.81	0.45	0.64
Accounts Receivable Turnover	9.64	3.63	2.67	7.63	7.20	6.52	9.71	9.95	7.75	7.04	6.48
Inventory Turnover	1.02	0.96	0.93	4.11	1.83	1.21	2.32	2.37	1.92	1.88	4.55
Fixed Asset Turnover	13.97	5.17	3.69	8.58	6.13	7.94	16.28	9.61	6.25	4.16	4.16
Accounts Payable Turnover	9.78	3.39	1.94	8.82	6.08	4.56	8.81	6.10	3.96	3.50	4.70
Days Sales Outstanding (DSO)	37.87	100.65	136.81	47.82	50.67	55.94	37.59	36.67	47.09	51.81	56.33
Days Inventory Outstanding (DIO)	358.69	378.56	393.58	88.79	199.54	301.69	157.23	153.85	190.13	193.94	80.17
Days Payable Outstanding (DPO)	37.31	107.57	188.62	41.38	60.03	79.98	41.42	59.83	92.09	104.18	77.61
Cash Conversion Cycle (CCC)	359.24	371.64	341.77	95.23	190.18	277.65	153.39	130.70	145.13	141.57	58.90
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	255	258	323	416	113	35	-23	2.36	4.60	6.03	4.00
Invested Capital Turnover	0.32	0.26	0.21	0.45	0.65	4.45	-1.95	3.17	1.55	1.29	10.55
Increase / (Decrease) in Invested Capital	-3.06	-65	-94	304	78	57	-25	-2.25	-1.43	2.04	6.82
Enterprise Value (EV)	1,110	690	737	1,491	1,213	322	185	74	22	24	12
Market Capitalization	1,204	716	778	1,552	1,306	331	223	82	21	27	20
Book Value per Share	$7.52	$7.67	$8.52	$11.48	$6.27	$2.12	$0.79	$0.74	$0.25	$0.69	$0.98
Tangible Book Value per Share	$2.74	$2.57	$2.51	$2.43	$3.54	($0.59)	$0.79	$0.74	$0.25	$0.51	$0.79
Total Capital	365	362	392	491	209	44	15	10	6.01	9.86	14
Total Debt	16	24	28	13	3.92	0.38	0.00	0.00	2.84	0.00	0.00
Total Long-Term Debt	5.00	18	24	6.64	0.67	0.00	0.00	0.00	2.84	0.00	0.00
Net Debt	-94	-26	-41	-62	-92	-8.57	-37	-7.73	1.44	-3.82	-9.94
Capital Expenditures (CapEx)	3.23	6.38	10	8.38	1.93	0.68	0.50	0.14	1.26	1.42	0.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)	22	41	35	20	12	10	4.97	1.76	2.09	1.42	0.97
Debt-free Net Working Capital (DFNWC)	127	85	98	89	102	17	36	8.42	3.49	5.25	11
Net Working Capital (NWC)	116	78	94	83	99	16	36	8.42	3.49	5.25	11
Net Nonoperating Expense (NNE)	15	52	136	-16	-6.35	1.50	28	1.78	4.65	1.48	1.11
Net Nonoperating Obligations (NNO)	-94	-80	-41	-62	-92	-8.57	-37	-7.73	1.44	-3.82	-9.94
Total Depreciation and Amortization (D&A)	8.19	11	16	13	5.07	1.80	0.34	0.37	0.46	0.31	0.33
Debt-free, Cash-free Net Working Capital to Revenue	27.22%	53.43%	46.03%	16.37%	24.82%	37.90%	25.16%	15.92%	25.39%	22.06%	15.60%
Debt-free Net Working Capital to Revenue	154.36%	111.67%	128.31%	75.01%	212.93%	61.46%	180.45%	76.37%	42.48%	81.36%	176.14%
Net Working Capital to Revenue	141.06%	103.39%	123.13%	69.98%	206.17%	60.08%	180.45%	76.37%	42.48%	81.36%	176.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.44)	($1.52)	($3.29)	($0.20)	$0.09	($0.09)	$0.18	($0.21)	($0.54)	($0.35)	($0.31)
Adjusted Weighted Average Basic Shares Outstanding	46.07M	43.72M	42.48M	42.09M	33.40M	19.46M	16.26M	14.12M	13.00M	12.45M	12.10M
Adjusted Diluted Earnings per Share	($0.44)	($1.52)	($3.29)	($0.20)	($0.03)	($0.09)	$0.14	($0.21)	($0.54)	($0.35)	($0.31)
Adjusted Weighted Average Diluted Shares Outstanding	46.07M	43.72M	43.21M	42.09M	33.40M	19.46M	21.63M	14.12M	13.00M	12.45M	12.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($0.09)	$0.00	($0.21)	($0.54)	($0.35)	($0.31)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	47M	45.30M	43.21M	38.50M	27.31M	19.46M	18.65M	13.26M	12.64M	12.18M	10.45M
Normalized Net Operating Profit after Tax (NOPAT)	-4.99	-18	-7.47	-21	-2.80	0.54	2.56	-0.74	-3.40	-3.51	-2.19
Normalized NOPAT Margin	-6.07%	-23.65%	-9.80%	-18.01%	-5.82%	1.97%	12.98%	-6.71%	-41.28%	-54.46%	-35.46%
Pre Tax Income Margin	-13.89%	-24.35%	-6.36%	-24.36%	-2.66%	-11.68%	-126.66%	-22.82%	-97.74%	-77.46%	-53.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-4,921.80	-3.36	-11.97	0.00	-17.62
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	512.68	-2.14	-8.38	0.00	-12.38
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-5,021.80	-3.78	-15.08	0.00	-20.92
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	412.68	-2.55	-11.49	0.00	-15.68
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.74%	-4.21%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.09%	-1.63%	312.66%	0.00%	-1.74%	-6.28%	-1.39%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	29.88%	42.88%	29.69%	-3.11%	-15.85%	64.47%	-42.15%	-27.87%	4.09%	-210.60%	20.55%
EBITDA Growth	117.34%	-51.61%	106.23%	76.04%	25.18%	-79.97%	-68.39%	97.19%	-213.49%	789.70%	2.84%
EBIT Growth	63.35%	-55.15%	90.39%	47.14%	25.19%	-81.76%	-31.40%	93.30%	-68.59%	599.52%	-3.87%
NOPAT Growth	63.03%	-54.60%	89.93%	73.70%	25.56%	-81.80%	-31.81%	86.12%	-70.77%	801.29%	-5.21%
Net Income Growth	95.62%	183.30%	94.15%	-103.15%	25.47%	69.59%	-182.37%	86.01%	-84.80%	-212.41%	-13,159.49%
EPS Growth	95.45%	181.82%	94.03%	-95.65%	31.25%	0.00%	-179.17%	86.63%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	138.59%	-28.82%	209.66%	183.69%	-65.01%	-70.59%	-392.71%	22.17%	65.77%	1,115.12%	-28.18%
Free Cash Flow Firm Growth	269.20%	-87.10%	-89.99%	-50.63%	-90.24%	-55.62%	7.20%	193.41%	129.07%	158.18%	112.39%
Invested Capital Growth	-16.69%	-1.19%	-1.87%	-6.20%	-4.94%	-20.20%	-15.71%	-11.99%	-23.75%	-22.46%	-12.39%
Revenue Q/Q Growth	385.97%	-127.39%	7.92%	-10.71%	-26.22%	-162.18%	-19.37%	-22.45%	-14.81%	-201.26%	0.53%
EBITDA Q/Q Growth	-98.19%	1,086.26%	257.53%	93.77%	49.42%	252.61%	-506.32%	80.55%	77.41%	1,383.05%	89.89%
EBIT Q/Q Growth	-115.01%	607.24%	46.00%	72.57%	43.73%	208.65%	-197.13%	61.18%	72.94%	882.53%	84.86%
NOPAT Q/Q Growth	-111.38%	786.38%	44.22%	72.40%	43.13%	252.32%	-45.61%	21.88%	72.39%	1,203.00%	84.67%
Net Income Q/Q Growth	-103.60%	831.59%	91.78%	-102.71%	23.62%	48.66%	-185.64%	25.63%	72.12%	-376.78%	85.84%
EPS Q/Q Growth	-103.70%	775.00%	91.11%	-104.55%	26.67%	50.75%	-191.30%	28.13%	0.00%	0.00%	86.05%
Operating Cash Flow Q/Q Growth	4.98%	-65.74%	-25.65%	244.34%	-293.64%	152.77%	43.26%	-184.59%	-134.52%	425.20%	115.09%
Free Cash Flow Firm Q/Q Growth	380.00%	122.65%	-74.03%	104.32%	159.34%	72.73%	28.05%	-59.63%	55.06%	317.26%	211.57%
Invested Capital Q/Q Growth	0.90%	-16.83%	0.17%	-0.90%	0.46%	-17.41%	-4.25%	0.44%	0.47%	-12.76%	-0.03%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	65.94%	0.00%	53.30%	52.57%	39.59%	0.00%	50.88%	37.71%	37.24%	0.00%	33.72%
EBITDA Margin	0.69%	0.00%	2.50%	-1.71%	-24.54%	0.00%	-52.06%	-6.92%	-27.61%	0.00%	-17.89%
Operating Margin	-5.09%	0.00%	-5.10%	-9.87%	-31.92%	0.00%	-65.65%	-36.35%	-36.08%	0.00%	-28.81%
EBIT Margin	-4.66%	0.00%	-4.79%	-9.57%	-31.15%	0.00%	-64.65%	-17.54%	-35.04%	0.00%	-28.46%
Profit (Net Income) Margin	-1.87%	0.00%	-5.57%	-73.14%	-32.22%	0.00%	-123.58%	-34.88%	-36.37%	0.00%	-25.32%
Tax Burden Percent	103.23%	165.19%	98.38%	289.94%	101.30%	-91.45%	185.68%	184.90%	100.68%	-54.23%	94.51%
Interest Burden Percent	38.92%	101.56%	118.24%	263.59%	102.09%	98.78%	102.95%	107.55%	103.11%	99.94%	94.12%
Effective Tax Rate	0.00%	-1.87%	0.00%	0.00%	0.00%	-1.42%	0.00%	0.00%	0.00%	-0.33%	0.00%
Return on Invested Capital (ROIC)	-1.11%	0.00%	-1.66%	-2.98%	-9.70%	0.00%	-18.16%	-11.11%	-11.00%	0.00%	-7.88%
ROIC Less NNEP Spread (ROIC-NNEP)	-1.78%	0.00%	1.46%	86.23%	0.98%	0.00%	44.82%	-3.03%	-1.33%	0.00%	-3.87%
Return on Net Nonoperating Assets (RNNOA)	0.31%	0.00%	-0.09%	-5.38%	-0.08%	0.00%	-3.52%	0.27%	0.14%	0.00%	0.45%
Return on Equity (ROE)	-0.79%	0.00%	-1.74%	-8.37%	-9.78%	0.00%	-21.68%	-10.84%	-10.86%	0.00%	-7.43%
Cash Return on Invested Capital (CROIC)	16.96%	-0.76%	-8.44%	-6.80%	-9.84%	16.82%	-1.21%	-4.39%	-1.27%	24.17%	-7.06%
Operating Return on Assets (OROA)	-1.03%	0.00%	-1.73%	-3.23%	-10.09%	0.00%	-19.39%	-5.90%	-11.55%	0.00%	-8.42%
Return on Assets (ROA)	-0.41%	0.00%	-2.02%	-24.69%	-10.43%	0.00%	-37.06%	-11.73%	-11.99%	0.00%	-7.49%
Return on Common Equity (ROCE)	-0.79%	0.00%	-1.74%	-8.37%	-9.78%	0.00%	-21.68%	-10.84%	-10.86%	0.00%	-7.43%
Return on Equity Simple (ROE_SIMPLE)	-2.95%	0.00%	-14.14%	-22.85%	-18.88%	0.00%	-30.79%	-23.69%	-40.80%	0.00%	-26.05%
Net Operating Profit after Tax (NOPAT)	-0.85	7.49	-1.09	-1.96	-7.09	16	-11	-7.44	-9.52	91	-8.22
NOPAT Margin	-3.56%	0.00%	-3.57%	-6.91%	-22.35%	0.00%	-45.95%	-25.45%	-25.26%	0.00%	-20.17%
Net Nonoperating Expense Percent (NNEP)	0.67%	5.70%	-3.11%	-89.22%	-10.68%	-51.90%	-62.98%	-8.08%	-9.67%	-271.86%	-4.00%
Return On Investment Capital (ROIC_SIMPLE)	-0.23%	2.05%	-	-	-	4.56%	-	-	-	23.12%	-
Cost of Revenue to Revenue	34.06%	0.00%	46.70%	47.43%	60.41%	0.00%	49.12%	62.29%	62.76%	0.00%	66.28%
SG&A Expenses to Revenue	48.04%	0.00%	37.13%	38.46%	40.77%	0.00%	45.87%	46.31%	39.37%	0.00%	29.24%
R&D to Revenue	9.21%	0.00%	6.71%	8.41%	11.14%	0.00%	15.86%	12.97%	11.01%	0.00%	8.41%
Operating Expenses to Revenue	71.02%	0.00%	58.40%	62.44%	71.51%	0.00%	116.53%	74.06%	73.32%	0.00%	62.53%
Earnings before Interest and Taxes (EBIT)	-1.12	7.43	-1.46	-2.71	-9.88	17	-15	-5.13	-13	91	-12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.16	9.06	0.76	-0.49	-7.79	19	-12	-2.02	-10	94	-7.29
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.04	3.45	3.55	3.07	2.52	2.12	1.81	2.73	2.62	2.14	2.37
Price to Tangible Book Value (P/TBV)	8.17	9.48	14.04	12.75	9.50	6.31	7.05	9.78	9.15	7.25	8.85
Price to Revenue (P/Rev)	12.23	14.64	8.06	7.23	6.12	9.43	4.46	6.32	5.76	10.21	6.26
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.81	4.36	3.71	3.18	2.64	2.68	1.86	2.87	2.79	2.28	2.52
Enterprise Value to Revenue (EV/Rev)	11.14	13.49	7.92	7.12	5.94	9.09	4.31	6.15	5.55	9.67	6.02
Enterprise Value to EBITDA (EV/EBITDA)	366.90	713.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	68.36	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	66.82	131.65	124.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	20.40	0.00	0.00	0.00	0.00	14.12	0.00	0.00	0.00	8.25	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.04	0.05	0.06	0.07	0.08	0.07	0.08	0.08	0.08	0.08	0.07
Long-Term Debt to Equity	0.01	0.01	0.03	0.04	0.05	0.05	0.07	0.07	0.07	0.07	0.06
Financial Leverage	-0.18	-0.25	-0.06	-0.06	-0.08	-0.17	-0.08	-0.09	-0.10	-0.12	-0.12
Leverage Ratio	1.16	1.18	1.21	1.20	1.23	1.23	1.21	1.18	1.18	1.19	1.17
Compound Leverage Factor	0.45	1.20	1.43	3.16	1.25	1.21	1.25	1.27	1.22	1.19	1.10
Debt to Total Capital	3.54%	4.37%	6.05%	6.42%	7.08%	6.60%	7.59%	7.10%	7.33%	7.11%	6.66%
Short-Term Debt to Total Capital	2.86%	3.00%	3.53%	3.09%	2.40%	1.74%	1.42%	0.53%	1.18%	1.01%	1.08%
Long-Term Debt to Total Capital	0.68%	1.37%	2.52%	3.33%	4.67%	4.86%	6.18%	6.57%	6.16%	6.10%	5.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	96.46%	95.63%	93.95%	93.58%	92.92%	93.40%	92.41%	92.90%	92.67%	92.89%	93.34%
Debt to EBITDA	4.86	10.25	-0.58	-0.45	-0.50	-3.99	-0.39	-0.41	-0.21	2.59	-0.30
Net Debt to EBITDA	-35.90	-60.62	0.53	0.32	0.49	4.34	0.28	0.40	0.25	-3.83	0.39
Long-Term Debt to EBITDA	0.94	3.21	-0.24	-0.23	-0.33	-2.94	-0.31	-0.38	-0.18	2.22	-0.25
Debt to NOPAT	-3.66	-3.19	-0.66	-0.53	-0.54	-1.45	-0.44	-0.45	-0.27	-6.72	-0.36
Net Debt to NOPAT	27.06	18.89	0.60	0.38	0.53	1.58	0.32	0.44	0.32	9.95	0.47
Long-Term Debt to NOPAT	-0.71	-1.00	-0.27	-0.27	-0.36	-1.07	-0.36	-0.42	-0.22	-5.77	-0.30
Altman Z-Score	14.49	13.73	11.60	10.29	6.74	5.20	3.95	6.77	6.06	5.74	7.25
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.73	4.54	2.78	2.86	2.89	2.86	2.74	3.04	2.81	3.11	3.68
Quick Ratio	3.53	3.48	1.62	1.69	1.65	1.23	1.54	1.85	1.80	2.17	2.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	51	11	4.74	18	8.93	82	47	37	92	184	44
Operating Cash Flow to CapEx	986.86%	215.88%	431.06%	649.15%	-1,257.02%	235.58%	-292.71%	-1,267.32%	-82.31%	176.64%	61.16%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.22	0.20	0.36	0.34	0.32	0.18	0.30	0.34	0.33	0.15	0.30
Accounts Receivable Turnover	6.33	9.64	6.75	6.07	5.61	3.63	4.73	5.23	5.98	2.67	5.88
Inventory Turnover	0.86	1.02	2.38	2.43	2.17	0.96	2.17	2.74	3.00	0.93	3.43
Fixed Asset Turnover	6.35	13.97	7.41	6.37	5.82	5.17	6.31	6.80	7.36	3.69	7.90
Accounts Payable Turnover	7.38	9.78	11.37	11.71	8.97	3.39	6.67	8.93	7.87	1.94	7.93
Days Sales Outstanding (DSO)	57.69	37.87	54.06	60.11	65.02	100.65	77.18	69.80	61.06	136.81	62.09
Days Inventory Outstanding (DIO)	424.08	358.69	153.26	149.93	168.07	378.56	168.03	133.44	121.82	393.58	106.43
Days Payable Outstanding (DPO)	49.48	37.31	32.10	31.17	40.67	107.57	54.74	40.89	46.39	188.62	46.03
Cash Conversion Cycle (CCC)	432.29	359.24	175.23	178.88	192.41	371.64	190.46	162.35	136.49	341.77	122.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	257	255	306	306	308	258	312	326	324	323	370
Invested Capital Turnover	0.31	0.32	0.46	0.43	0.43	0.26	0.40	0.44	0.44	0.21	0.39
Increase / (Decrease) in Invested Capital	-51	-3.06	-5.83	-20	-16	-65	-58	-44	-101	-94	-52
Enterprise Value (EV)	978	1,110	1,136	971	815	690	581	934	906	737	932
Market Capitalization	1,073	1,204	1,155	986	840	716	601	960	940	778	969
Book Value per Share	$7.50	$7.52	$7.05	$6.98	$7.36	$7.67	$7.63	$8.10	$8.37	$8.52	$9.58
Tangible Book Value per Share	$2.80	$2.74	$1.78	$1.68	$1.95	$2.57	$1.96	$2.26	$2.40	$2.51	$2.57
Total Capital	366	365	346	344	359	362	359	379	386	392	437
Total Debt	13	16	21	22	25	24	27	27	28	28	29
Total Long-Term Debt	2.50	5.00	8.74	11	17	18	22	25	24	24	24
Net Debt	-96	-94	-19	-16	-25	-26	-20	-26	-34	-41	-38
Capital Expenditures (CapEx)	0.18	0.76	1.11	1.00	0.36	0.98	1.50	0.61	3.30	4.45	2.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	25	22	35	34	36	41	38	36	35	35	42
Debt-free Net Working Capital (DFNWC)	114	127	69	68	82	85	79	83	90	98	104
Net Working Capital (NWC)	103	116	57	57	73	78	74	81	85	94	99
Net Nonoperating Expense (NNE)	-0.40	-4.97	0.61	19	3.13	31	18	2.76	4.19	140	2.10
Net Nonoperating Obligations (NNO)	-96	-94	-19	-16	-25	-80	-20	-26	-34	-41	-38
Total Depreciation and Amortization (D&A)	1.28	1.64	2.23	2.23	2.10	2.17	2.97	3.11	2.80	2.75	4.31
Debt-free, Cash-free Net Working Capital to Revenue	28.80%	27.22%	24.46%	24.80%	26.48%	53.43%	28.36%	23.99%	21.50%	46.03%	27.14%
Debt-free Net Working Capital to Revenue	129.73%	154.36%	48.44%	49.85%	59.48%	111.67%	58.83%	54.46%	55.14%	128.31%	66.96%
Net Working Capital to Revenue	117.83%	141.06%	39.90%	42.07%	53.20%	103.39%	55.06%	53.13%	52.36%	123.13%	63.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.01)	$0.27	($0.04)	($0.45)	($0.22)	($0.33)	($0.67)	($0.23)	($0.32)	($1.15)	($0.23)
Adjusted Weighted Average Basic Shares Outstanding	46.69M	46.07M	46.18M	25.29M	45.43M	43.72M	43.57M	43.44M	43.03M	42.48M	42.65M
Adjusted Diluted Earnings per Share	($0.01)	$0.27	($0.04)	($0.45)	($0.22)	($0.33)	($0.67)	($0.23)	$0.00	$0.00	($0.23)
Adjusted Weighted Average Diluted Shares Outstanding	47.13M	46.07M	46.18M	46.00M	45.43M	43.72M	43.57M	43.44M	43.46M	43.07M	42.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	47.56M	47M	46.39M	46.14M	46.03M	45.30M	44.03M	43.49M	43.46M	43.21M	42.77M
Normalized Net Operating Profit after Tax (NOPAT)	-0.85	5.15	-1.09	-1.96	-6.92	11	-6.12	-8.08	-9.02	62	-6.58
Normalized NOPAT Margin	-3.56%	0.00%	-3.57%	-6.91%	-21.82%	0.00%	-25.97%	-27.64%	-23.92%	0.00%	-16.14%
Pre Tax Income Margin	-1.81%	0.00%	-5.66%	-25.23%	-31.80%	0.00%	-66.56%	-18.87%	-36.13%	0.00%	-26.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.09%	-0.12%

Frequently Asked Questions About BioLife Solutions' Financials

When does BioLife Solutions's fiscal year end?

According to the most recent income statement we have on file, BioLife Solutions' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has BioLife Solutions' net income changed over the last 10 years?

BioLife Solutions' net income appears to be on an upward trend, with a most recent value of -$20.18 million in 2024, rising from -$3.30 million in 2014. The previous period was -$68.00 million in 2023. See BioLife Solutions' forecast for analyst expectations on what’s next for the company.

What is BioLife Solutions's operating income?

BioLife Solutions's total operating income in 2024 was -$7.13 million, based on the following breakdown:

Total Gross Profit: $53.67 million
Total Operating Expenses: $60.80 million

How has BioLife Solutions revenue changed over the last 10 years?

Over the last 10 years, BioLife Solutions' total revenue changed from $6.19 million in 2014 to $82.25 million in 2024, a change of 1,228.7%.

How much debt does BioLife Solutions have?

BioLife Solutions' total liabilities were at $50.58 million at the end of 2024, a 32.6% decrease from 2023, and a 2,267.2% increase since 2014.

How much cash does BioLife Solutions have?

In the past 10 years, BioLife Solutions' cash and equivalents has ranged from $1.41 million in 2016 to $95.39 million in 2024, and is currently $95.39 million as of their latest financial filing in 2024.

How has BioLife Solutions' book value per share changed over the last 10 years?

Over the last 10 years, BioLife Solutions' book value per share changed from 0.98 in 2014 to 7.52 in 2024, a change of 670.0%.

Related Companies

This page (NASDAQ:BLFS) was last updated on 6/1/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Financials

Frequently Asked Questions About BioLife Solutions' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Financials

Annual Income Statements for BioLife Solutions

Quarterly Income Statements for BioLife Solutions

Annual Cash Flow Statements for BioLife Solutions

Quarterly Cash Flow Statements for BioLife Solutions

Annual Balance Sheets for BioLife Solutions

Quarterly Balance Sheets for BioLife Solutions

Annual Metrics And Ratios for BioLife Solutions

Quarterly Metrics And Ratios for BioLife Solutions

Frequently Asked Questions About BioLife Solutions' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools